Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Monopolar and Bipolar Current RFA Knife in POEM

NCT: NCT05272046 · ACTIVE_NOT_RECRUITING

NCT IDNCT05272046
StatusACTIVE_NOT_RECRUITING
Start Date2022-02-22
Completion2026-12-01

Brief Summary

Per Oral Endoscopic Myotomy (POEM) is performed for various esophageal muscular disorders, including achalasia and other spastic esophageal conditions. It is performed with the standard endoscope and involves dissecting the esophageal muscle sphincter. The procedure is typically completed using standard monopolar energy, which are effective, but can be associated with post-procedural pain. More importantly, frequent exchange of various instruments are required in order to cut the right layers and to stop bleeding. The Speedboat-RSD is FDA approved for dissection of various tissue within the gastrointestinal tract tract but only a few studies have evaluated its use in POEM. Currently, the investigators have been performing EGD with POEM procedures using Speedboat-RSD as a standard of care procedure. The investigators would like to compare the performance of the standard monopolar ERBE knife to the bipolar Speedboat-RSD knife in POEM. The investigators hypothesize the bipolar knife will allow for efficient completion of the POEM procedure with less post procedural pain.

Frequently Asked Questions

What is Monopolar and Bipolar Current RFA Knife in POEM?

Monopolar and Bipolar Current RFA Knife in POEM is a clinical trial registered under NCT05272046. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05272046?

The current status of NCT05272046 (Monopolar and Bipolar Current RFA Knife in POEM) is: ACTIVE_NOT_RECRUITING.

When did Monopolar and Bipolar Current RFA Knife in POEM start?

Monopolar and Bipolar Current RFA Knife in POEM started on 2022-02-22.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.